Kingsview Wealth Management LLC Sells 190 Shares of Becton, Dickinson and Company (NYSE:BDX)

Kingsview Wealth Management LLC lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,952 shares of the medical instruments supplier’s stock after selling 190 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $897,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of BDX. CWM LLC lifted its position in Becton, Dickinson and Company by 0.6% during the third quarter. CWM LLC now owns 8,965 shares of the medical instruments supplier’s stock valued at $2,161,000 after purchasing an additional 57 shares during the last quarter. Sound Income Strategies LLC lifted its position in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Paladin Wealth LLC bought a new position in Becton, Dickinson and Company during the third quarter valued at $150,000. ORG Wealth Partners LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth about $240,000. Finally, CX Institutional lifted its holdings in shares of Becton, Dickinson and Company by 128.6% in the 3rd quarter. CX Institutional now owns 1,175 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 661 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on BDX shares. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Trading Down 0.0 %

NYSE BDX opened at $229.50 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13. The company has a market capitalization of $66.56 billion, a price-to-earnings ratio of 38.12, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. The company’s 50-day simple moving average is $232.20 and its two-hundred day simple moving average is $233.99. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts forecast that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 69.10%.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Jeffrey William Henderson bought 1,500 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was bought at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the purchase, the director now directly owns 8,015 shares of the company’s stock, valued at approximately $1,872,464.30. This trade represents a 23.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 in the last 90 days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.